Reviva Pharmaceuticals Holdings, Inc. (RVPH)
NASDAQ: RVPH · Real-Time Price · USD
0.8668
-0.0122 (-1.39%)
At close: Apr 29, 2026, 4:00 PM EDT
0.8800
+0.0132 (1.52%)
After-hours: Apr 29, 2026, 7:42 PM EDT
RVPH Employees
Reviva Pharmaceuticals Holdings had 14 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
14
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,418,922
Market Cap
11.10M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 14 | 0 | - |
| Dec 31, 2024 | 14 | -1 | -6.67% |
| Dec 31, 2023 | 15 | 5 | 50.00% |
| Dec 31, 2022 | 10 | 5 | 100.00% |
| Dec 31, 2021 | 5 | 0 | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| CytoMed Therapeutics | 43 |
| PMGC Holdings | 34 |
| Imunon | 25 |
| BioLineRx | 24 |
| Kiora Pharmaceuticals | 13 |
| Cellectar Biosciences | 11 |
| Quoin Pharmaceuticals | 5 |
| CDT Equity | 4 |
RVPH News
- 2 days ago - Reviva Pharmaceuticals Holdings Transcript: Study update - Transcripts
- 4 weeks ago - Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 5 weeks ago - What's Behind The Drop In Reviva Pharmaceuticals Stock? - Benzinga
- 5 weeks ago - Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering - GlobeNewsWire
- 6 weeks ago - Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering - GlobeNewsWire
- 3 months ago - Reviva Pharmaceuticals Holdings Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit - Transcripts
- 4 months ago - Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum - GlobeNewsWire
- 4 months ago - FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug - Benzinga